- Home
- QLYS vs MRUS Comparison
QLYS vs MRUS Comparison
Compare QLYS & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLYS
- MRUS
- Stock Information
- Founded
- QLYS 1999
- MRUS 2003
- Country
- QLYS United States
- MRUS Netherlands
- Employees
- QLYS N/A
- MRUS N/A
- Industry
- QLYS Computer Software: Prepackaged Software
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- QLYS Technology
- MRUS Health Care
- Exchange
- QLYS Nasdaq
- MRUS Nasdaq
- Market Cap
- QLYS 5.1B
- MRUS 2.9B
- IPO Year
- QLYS 2012
- MRUS 2016
- Fundamental
- Price
- QLYS $138.59
- MRUS $42.50
- Analyst Decision
- QLYS Hold
- MRUS Strong Buy
- Analyst Count
- QLYS 18
- MRUS 12
- Target Price
- QLYS $154.19
- MRUS $87.92
- AVG Volume (30 Days)
- QLYS 296.4K
- MRUS 613.2K
- Earning Date
- QLYS 02-05-2025
- MRUS 02-26-2025
- Dividend Yield
- QLYS N/A
- MRUS N/A
- EPS Growth
- QLYS 22.85
- MRUS N/A
- EPS
- QLYS 4.53
- MRUS N/A
- Revenue
- QLYS $592,950,000.00
- MRUS $35,932,000.00
- Revenue This Year
- QLYS $11.24
- MRUS N/A
- Revenue Next Year
- QLYS $7.62
- MRUS $57.37
- P/E Ratio
- QLYS $30.96
- MRUS N/A
- Revenue Growth
- QLYS 9.66
- MRUS N/A
- 52 Week Low
- QLYS $119.17
- MRUS $27.11
- 52 Week High
- QLYS $201.03
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- QLYS 45.77
- MRUS 45.33
- Support Level
- QLYS $137.42
- MRUS $41.23
- Resistance Level
- QLYS $142.41
- MRUS $43.51
- Average True Range (ATR)
- QLYS 3.26
- MRUS 1.61
- MACD
- QLYS -0.97
- MRUS 0.21
- Stochastic Oscillator
- QLYS 30.83
- MRUS 43.84
About QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.